Alabama Hospital Adopts IceCure’s Cryoablation System for Breast Cancer

Event summary

  • Thomas Hospital of Fairhope, part of Infirmary Health, installed IceCure’s ProSense® system, becoming the first facility in Alabama to offer breast cancer cryoablation.
  • The purchase was funded by the Thomas Hospital Foundation following the FDA’s October 2025 clearance for ProSense® in low-risk breast cancer.
  • Dr. Katelin Holmes, Medical Director of Breast Surgical Services at Thomas Hospital, will select patients for the procedures, with some treatments scheduled to begin in February 2026.
  • ProSense® is the first and only medical device with FDA marketing authorization for the local treatment of low-risk breast cancer in women aged 70 and above.

The big picture

IceCure’s ProSense® system represents a shift toward minimally invasive alternatives to surgical tumor removal, particularly for low-risk breast cancer patients. The FDA’s October 2025 clearance and the subsequent adoption by Thomas Hospital signal growing acceptance of cryoablation as a viable treatment option. The strategic significance lies in IceCure’s ability to expand its footprint in the U.S. healthcare system, where minimally invasive procedures are increasingly preferred for their cost-efficiency and patient-friendly outcomes.

What we're watching

Adoption Pace
Whether the FDA clearance will accelerate ProSense® installations in other hospitals, particularly in regions with high breast cancer prevalence.
Patient Outcomes
How the efficacy and safety of ProSense® in real-world settings compare to clinical trial results, which could influence broader adoption.
Competitive Response
How competitors in the cryoablation space react to IceCure’s growing market presence, particularly in the low-risk breast cancer segment.

Related topics

Oncology